Published on 27/12/2025
Compliance Playbook for Comparing Video Conferencing Tools in Virtual Site Visits
Introduction: The Role of Video Conferencing in Remote Clinical Oversight
As decentralized and hybrid clinical trial models become standard, video conferencing tools have emerged as a primary mechanism for conducting virtual site visits. These tools are used to facilitate discussions between site personnel and monitors, perform remote source data verification (rSDV), and document interactions for inspection readiness. However, not all video conferencing platforms are built to meet regulatory expectations set by FDA, EMA, and ICH GCP guidelines.
In this compliance playbook, we compare commonly used video conferencing platforms in clinical research, identify their strengths and weaknesses from a regulatory standpoint, and offer guidance on documentation, validation, and CAPA practices related to virtual site visit technology.
Key Regulatory Expectations for Video Conferencing Tools
When used in clinical trial oversight, video conferencing tools must meet certain compliance benchmarks:
- 21 CFR Part 11 / Annex 11 Compliance: Tools should provide audit trails, electronic signatures, and validation documentation.
- Security: End-to-end encryption and HIPAA compliance for confidentiality.
- Access Controls: Role-based access for CRAs, investigators, and sponsor representatives.
- Documentation: Meeting logs, screen share audit trails, and inclusion in eTMF or QMS systems.
- Validation: Sponsors or
Platforms lacking these controls may be challenged during regulatory inspections, potentially leading to CAPA requirements or findings.
Comparison Table of Commonly Used Video Tools
The following table compares features of major video conferencing platforms often used in clinical trials:
| Platform | Part 11/Annex 11 Compliant | Audit Trail | Validation Package Available | Recommended Use |
|---|---|---|---|---|
| Microsoft Teams (Enterprise) | Yes (with GxP Add-on) | Yes (via Microsoft Purview) | Yes | Formal virtual visits with data review |
| Zoom for Healthcare | Partial (with BAA) | Limited | Requires sponsor validation | Meetings, training, non-critical visits |
| WebEx Enterprise | Yes | Yes | Yes | High-security virtual oversight |
| Google Meet | No | No | No | Internal site communication only |
Case Study: EMA Review of Video Tool Validation
In a multi-center European trial, a sponsor conducted all site initiation visits using Zoom. During EMA inspection, auditors requested validation evidence for Zoom’s platform, which the sponsor failed to provide. As a result, an observation was issued citing lack of system qualification.
The sponsor responded with a CAPA plan, transitioning future visits to Microsoft Teams with validation SOPs, user training records, and session logs uploaded to the eTMF.
Best Practices for Tool Selection and SOP Development
When selecting a video platform for virtual visits, sponsors and CROs should follow a standardized approach that includes:
- System Qualification: Conduct formal validation for any tool that influences trial data or decision-making.
- Vendor Assessment: Perform audits or due diligence on third-party vendors providing conferencing solutions.
- SOP Development: Create SOPs that cover meeting initiation, screen-sharing protocols, and documentation requirements.
- Data Integrity Controls: Ensure session recordings, shared screens, and chat transcripts are saved or summarized.
- eTMF Archival: Upload visit summaries, agendas, and training documentation to the eTMF or equivalent system.
Managing CAPA for Video Tool Failures
When video platform issues disrupt trial oversight or site communication, the resulting deviations must be captured in the monitoring log or deviation tracker. Common issues include:
- Session disconnection mid-review
- Unauthorized recording by a site user
- Unavailability of audit trails
- Failure to verify site screen-sharing controls
Each of these should be linked to a root cause analysis and followed by CAPA documentation. Corrective measures may include transitioning to a validated tool or retraining users on SOP-compliant video use.
Regulatory Guidance and External Resources
Agencies have not published platform-specific rules, but expect that sponsors demonstrate how oversight is maintained. The following resources offer insight:
- NIHR Guidance on Remote Monitoring and Communication Tools
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency
- ICH E6(R3) Draft – Section on Digital Health Tools
Checklist for Inspection-Ready Video Conferencing Use
The following checklist can help ensure compliance during sponsor QA audits or regulatory inspections:
- Validated conferencing platform in use
- SOP for video-based visits available and version controlled
- Site and CRA training documented
- Logs of all sessions with timestamps and participant list
- Summaries of discussions, shared documents captured in CRA visit report
- eTMF contains all relevant artifacts
Conclusion: Choose Compliance Over Convenience
While ease of use is important, video conferencing tools must be selected based on regulatory suitability, validation capability, and security. With increasing reliance on virtual models, sponsors must elevate their video platform strategy from an IT decision to a core compliance priority. SOPs, training, CAPA planning, and inspection readiness must align to create a seamless and audit-proof virtual site visit experience.